Imaging services firm Raytel'stender offer for Medical Diagnostics has been rejected by MDI'sboard of directors. MDI has also filed suit against Raytel andimplemented a stockholders' rights package to derail Raytel'sbid. Raytel, of San Mateo, CA,
Imaging services firm Raytel'stender offer for Medical Diagnostics has been rejected by MDI'sboard of directors. MDI has also filed suit against Raytel andimplemented a stockholders' rights package to derail Raytel'sbid.
Raytel, of San Mateo, CA, announced last month that it was preparingto launch a tender offer for all outstanding shares of MDI, ofBurlington, MA (SCAN 12/14/94). On Dec. 16, MDI's board of directorsresponded to the offer by rejecting Raytel's bid and urging thecompany's stockholders not to tender their shares to Raytel.
MDI's board adopted two additional strategies in its defense.It established a stockholders' rights plan intended to preventRaytel or any third party from taking control of MDI without negotiatingfirst with the board to secure a deal that is fair to shareholders.It also filed a lawsuit in U.S. District Court of Delaware seekingto enjoin Raytel from carrying out its tender offer.
A hearing on the lawsuit is expected to take place in January.Meanwhile, Raytel has until Jan. 3 to complete the tender offer,although the deadline may be extended.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.